The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
Schiff, M, Pritchard, C, Huffstutter, J E, Rodriguez-Valverde, V, Durez, P, Zhou, X, Li, T, Bahrt, K, Kelly, S, Le Bars, M, Genovese, M CVolume:
68
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/ard.2008.099218
Date:
November, 2009
File:
PDF, 336 KB
english, 2009